Blurbs

Robert W. Baird Maintains Their Buy Rating on Laboratory (LH)

Robert W. Baird analyst Eric Coldwell maintained a Buy rating on Laboratory (LHResearch Report) on February 10 and set a price target of $360.00. The company’s shares closed last Friday at $276.26.

According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 12.4% and a 61.0% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, AmerisourceBergen, and Cardinal Health.

Currently, the analyst consensus on Laboratory is a Strong Buy with an average price target of $344.67, a 21.6% upside from current levels. In a report issued on February 11, Wells Fargo also maintained a Buy rating on the stock with a $320.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Laboratory’s market cap is currently $25.72B and has a P/E ratio of 11.34.

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment involves in providing drug development solutions, to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.

Read More on LH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos